Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ECE2-HTR3D

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ECE2-HTR3D
	FusionPDB ID: 24866
	FusionGDB2.0 ID: 24866
		Hgene	Tgene
	Gene symbol	ECE2	HTR3D
	Gene ID	110599583	200909
	Gene name	EEF1AKMT4-ECE2 readthrough	5-hydroxytryptamine receptor 3D
	Synonyms	ECE-2\|ECE2	5HT3D
	Cytomap	3q27.1	3q27.1
	Type of gene	protein-coding	protein-coding
	Description	EEF1AKMT4-ECE2 readthrough transcript proteinEndothelin-converting enzyme 2	5-hydroxytryptamine receptor 3D5-hydroxytryptamine (serotonin) receptor 3 family member D5-hydroxytryptamine (serotonin) receptor 3D, ionotropic5-hydroxytryptamine receptor 3 subunit Dserotonin 5-HT-3D receptorserotonin receptor 3D
	Modification date	20200303	20200313
	UniProtAcc	P0DPD6 Main function of 5'-partner protein: FUNCTION: Converts big endothelin-1 to endothelin-1. Also involved in the processing of various neuroendocrine peptides, including neurotensin, angiotensin I, substance P, proenkephalin-derived peptides, and prodynorphin-derived peptides. May play a role in amyloid-beta processing (By similarity). {ECO:0000250\|UniProtKB:B2RQR8, ECO:0000269\|PubMed:12560336}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000324557, ENST00000402825, ENST00000357474, ENST00000359140, ENST00000404464,	ENST00000382489, ENST00000334128, ENST00000428798, ENST00000453435,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	4 X 3 X 1=12	3 X 3 X 2=18
	# samples	2	3
	** MAII score	log2(2/12*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0	log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0
Fusion gene context	PubMed: ECE2 [Title/Abstract] AND HTR3D [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ECE2 [Title/Abstract] AND HTR3D [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ECE2(183967678)-HTR3D(183756196), # samples:1
Anticipated loss of major functional domain due to fusion event.	ECE2-HTR3D seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. ECE2-HTR3D seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:183967678/chr3:183756196)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ECE2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across HTR3D (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000324557	ECE2	chr3	183967678	+	ENST00000334128	HTR3D	chr3	183756196	+	1081	241	45	686	213
ENST00000324557	ECE2	chr3	183967678	+	ENST00000428798	HTR3D	chr3	183756196	+	687	241	45	686	213
ENST00000324557	ECE2	chr3	183967678	+	ENST00000453435	HTR3D	chr3	183756196	+	912	241	45	686	213
ENST00000402825	ECE2	chr3	183967678	+	ENST00000334128	HTR3D	chr3	183756196	+	1036	196	0	641	213
ENST00000402825	ECE2	chr3	183967678	+	ENST00000428798	HTR3D	chr3	183756196	+	642	196	0	641	213
ENST00000402825	ECE2	chr3	183967678	+	ENST00000453435	HTR3D	chr3	183756196	+	867	196	0	641	213

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000324557	ENST00000334128	ECE2	chr3	183967678	+	HTR3D	chr3	183756196	+	0.13006385	0.8699361
ENST00000324557	ENST00000428798	ECE2	chr3	183967678	+	HTR3D	chr3	183756196	+	0.09403603	0.9059639
ENST00000324557	ENST00000453435	ECE2	chr3	183967678	+	HTR3D	chr3	183756196	+	0.07998673	0.92001325
ENST00000402825	ENST00000334128	ECE2	chr3	183967678	+	HTR3D	chr3	183756196	+	0.15779898	0.842201
ENST00000402825	ENST00000428798	ECE2	chr3	183967678	+	HTR3D	chr3	183756196	+	0.12582572	0.8741743
ENST00000402825	ENST00000453435	ECE2	chr3	183967678	+	HTR3D	chr3	183756196	+	0.100414045	0.899586

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ECE2-HTR3D

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ECE2	chr3	183967678	HTR3D	chr3	183756196	196	65	EPELRPEDRILVLGVYFALCLSLMVG
ECE2	chr3	183967678	HTR3D	chr3	183756196	241	65	EPELRPEDRILVLGVYFALCLSLMVG

Top

Potential FusionNeoAntigen Information of ECE2-HTR3D in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ECE2-HTR3D_183967678_183756196.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	HLA-A32:13	RILVLGVYF	0.936	0.7901	8	17
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	HLA-B73:01	DRILVLGVYFA	0.9944	0.5393	7	18
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	HLA-A32:01	RILVLGVYF	0.9832	0.7915	8	17

Top

Potential FusionNeoAntigen Information of ECE2-HTR3D in HLA II

ECE2-HTR3D_183967678_183756196.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-0303	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-0307	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-0315	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-0324	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1107	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1113	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1117	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1134	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1152	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1189	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1343	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1344	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1354	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1394	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1401	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1404	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1405	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1407	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1408	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1411	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1416	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1417	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1418	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1421	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1423	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1426	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1428	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1431	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1432	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1434	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1435	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1438	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1443	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1445	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1450	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1454	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1455	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1456	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1458	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1459	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1460	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1461	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1462	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1464	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1465	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1470	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1471	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1472	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1474	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1475	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1476	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1479	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1480	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1481	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1482	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1486	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1487	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1488	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1490	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1491	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1495	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1496	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1497	EPELRPEDRILVLGV	0	15
ECE2-HTR3D	chr3	183967678	chr3	183756196	241	DRB1-1499	EPELRPEDRILVLGV	0	15

Top

Fusion breakpoint peptide structures of ECE2-HTR3D

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
1611	EDRILVLGVYFALC	ECE2	HTR3D	chr3	183967678	chr3	183756196	241

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ECE2-HTR3D

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	1611	EDRILVLGVYFALC	-7.9962	-8.1096
HLA-B14:02	3BVN	1611	EDRILVLGVYFALC	-5.70842	-6.74372
HLA-B52:01	3W39	1611	EDRILVLGVYFALC	-6.83737	-6.95077
HLA-B52:01	3W39	1611	EDRILVLGVYFALC	-4.4836	-5.5189
HLA-A11:01	4UQ2	1611	EDRILVLGVYFALC	-10.0067	-10.1201
HLA-A11:01	4UQ2	1611	EDRILVLGVYFALC	-9.03915	-10.0745
HLA-A24:02	5HGA	1611	EDRILVLGVYFALC	-6.56204	-6.67544
HLA-A24:02	5HGA	1611	EDRILVLGVYFALC	-5.42271	-6.45801
HLA-B44:05	3DX8	1611	EDRILVLGVYFALC	-7.85648	-8.89178
HLA-B44:05	3DX8	1611	EDRILVLGVYFALC	-5.3978	-5.5112
HLA-A02:01	6TDR	1611	EDRILVLGVYFALC	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ECE2-HTR3D

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ECE2-HTR3D	chr3	183967678	chr3	183756196	7	18	DRILVLGVYFA	ACCGTATCCTTGTGCTAGGTGTCTACTTCGCCC
ECE2-HTR3D	chr3	183967678	chr3	183756196	8	17	RILVLGVYF	GTATCCTTGTGCTAGGTGTCTACTTCG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
ECE2-HTR3D	chr3	183967678	chr3	183756196	0	15	EPELRPEDRILVLGV	AGCCGGAGCTGCGGCCCGAGGACCGTATCCTTGTGCTAGGTGTCT

Top

Information of the samples that have these potential fusion neoantigens of ECE2-HTR3D

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LUSC	ECE2-HTR3D	chr3	183967678	ENST00000324557	chr3	183756196	ENST00000334128	TCGA-56-5898

Top

Potential target of CAR-T therapy development for ECE2-HTR3D

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000382489

233_253

455.0

Transmembrane

Helical%3B Name%3D1

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000382489

265_285

455.0

Transmembrane

Helical%3B Name%3D2

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000382489

307_327

455.0

Transmembrane

Helical%3B Name%3D3

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000382489

432_452

455.0

Transmembrane

Helical%3B Name%3D4

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000428798

265_285

405.0

Transmembrane

Helical%3B Name%3D2

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000428798

307_327

405.0

Transmembrane

Helical%3B Name%3D3

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000428798

432_452

405.0

Transmembrane

Helical%3B Name%3D4

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000453435

233_253

234.0

Transmembrane

Helical%3B Name%3D1

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000453435

265_285

234.0

Transmembrane

Helical%3B Name%3D2

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000453435

307_327

234.0

Transmembrane

Helical%3B Name%3D3

Tgene

HTR3D

chr3:183967678

chr3:183756196

ENST00000453435

432_452

234.0

Transmembrane

Helical%3B Name%3D4

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to ECE2-HTR3D

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ECE2-HTR3D

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)